Tele: 561.316.3330
Breaking Medical Device News

Monday, September 20, 2021

MEDICAL DEVICE NEWS MAGAZINE

A DIGITAL PUBLICATION FOR THE PRACTICING MEDICAL SPECIALIST, INDUSTRY EXECUTIVE AND INVESTOR
HomeAroa BiosurgeryAroa Biosurgery Launches Large Format Endoform ®

Aroa Biosurgery Launches Large Format Endoform ®

Used for the Treatment of Larger, More Complex Wounds

February 7, 2020

Aroa Biosurgery, the Auckland-based privately held soft-tissue repair company, has now launched a large format version of its Endoform® Natural product.

The largest of Aroa’s wound care products, the 8.5 by 6-inch device has been launched in the United States and Canadian markets, following its recent approval for reimbursement within the U.S. healthcare system.

Aroa Biosurgery Chief Executive, Brian Ward said this large-format version of Endoform® Natural addresses the growing need to treat large wounds with a single sheet of their extracellular matrix-based product and provides more options for clinicians.

“We saw a need to offer Healthcare Providers a simple option for larger and often more difficult-to-treat wounds arising from trauma and complications from surgical wounds, or other diseases where healing is impaired. This format is also suitable for wounds such as chronic wounds and venous leg ulcers.

“We are also seeing that Endoform® Natural is increasingly being used in conjunction with negative pressure wound therapy, and this large-format will be particularly useful in these treatment applications.”

Aroa Biosurgery intends to make the large format available in a range of global markets as and when regulatory approvals are granted.

“Aroa is committed to having solutions for a wide variety of wounds and wound sizes, and to partnering with clinicians to ensure there are effective solutions for patients presenting with an array of challenging wounds,” says Brian Ward.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected

spot_img

Don't Miss

Mark Foster Joins Xenocor BOD

Foster is a versatile and visionary C-Suite executive who brings 20 years of general management and leadership experience from both venture-backed growth-stage organizations and world-class medical device companies

Hinge Health Acquires the Most Advanced Computer Vision Technology for Tracking Human Motion

CEO Daniel Perez explained, “We won’t stop investing in technology to deliver the most patient-centered digital clinic that improves member experience and outcomes while reducing costs. wrnch allows us to take a giant leap forward in all respects.”

Dale W Wood Congratulates the Huma Team on Raising $130 Million

Major health and technology companies across the world have committed upwards of $130 million to Huma Therapeutics, the health-tech company backed by Dale Ventures.

Rhaeos Awarded $4 Million NIH SBIR Grant

Under the NIH SBIR grant, Rhaeos will leverage their existing wireless sensor hardware to provide additional quantitative flow data to the clinician, giving insight into this currently inaccessible and highly relevant shunt performance metric.

Gynesonics Announces FDA Clearance of Next Generation Sonata System

“This clearance brings significant system improvements that expand the location of fibroids that can be treated while allowing the physician to control all aspects of the treatment from within the sterile field,” said Jiayu Chen, Ph.D. Vice President, Engineering and Advanced Technologies at Gynesonics.

Blackrock Neurotech Invests In Groundbreaking Auditory Nerve Implant With University Of Minnesota And MED-EL

The new investment will enable the development and translation of a new ANI through preclinical studies and later, a pilot clinical trial, where the ANI is then implanted in up to three deaf patients.

Jonathan Chapman: New President/CEO of Trividia Health

Chapman said, “I’m honored to join the Trividia team as President and CEO. This organization has a long history of leadership within the healthcare industry as a provider of accurate, accessible, and affordable point-of-care solutions for the management of diabetes.”

SOLOPASS® System (Bedside Neuro-Navigation Device) Receives FDA 510(k) Clearance

inTRAvent’s SOLOPASS® system brings simple, portable, bedside neuro-navigation into the intensive care unit.

By using this website you agree to accept Medical Device News Magazine Privacy Policy